Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate TT-816, a Novel Oral Immune Response Modifier, in Combination with KEYTRUDA® (pembrolizumab)
Medical Marijuana Program Connection
JANUARY 20, 2023
SAN FRANCISCO–(BUSINESS WIRE)–Teon Therapeutics (Teon), a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled. Read More
52 
Let's personalize your content